INTRODUCTION: Pelvic inflammatory disease is caused by infection of the upper female genital tract and is often asymptomatic. Pelvic inflammatory disease is the most common gynaecological reason for admission to hospital in the US, and is diagnosed in approximately 1% of women aged 16 to 45 years consulting their GP in England and Wales. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: How do different antimicrobial regimens compare when treating women with confirmed pelvic inflammatory disease? What are the effects of routine antibiotic prophylaxis to prevent pelvic inflammatory disease before intrauterine contraceptive device (IUD) insertion? We searched: Medline, Embase, The Cochrane Library, and other important databases up to September 2013 (Clinical Evidence reviews are updated periodically; please check our website for the most up to date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 13 RCTs or systematic reviews of RCTs that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review, we present information relating to the effectiveness and safety of the following interventions: antibiotics (oral, parenteral, different durations, different regimens) and routine antibiotic prophylaxis (before intrauterine device insertion in women at high risk or low risk).
SEARCH AND APPRAISAL SUMMARY
The update literature search for this review was carried out from the date of the last search, May 2007 to September 2013. For more information on the electronic databases searched and criteria applied during assessment of studies for potential relevance to the review, please see the Methods section. Searching of electronic databases retrieved 97 studies. After de-duplication and removal of conference abstracts, 35 records were screened for inclusion in the review. Appraisal of titles and abstracts led to the exclusion of 27 studies and the further review of 8 full publications. Of the 8 full articles evaluated, 1 systematic review and 3 RCTs were added at this update.
DEFINITION
Pelvic inflammatory disease (PID) is inflammation and infection of the upper genital tract in women, typically involving the uterus and adnexae. Mild-to-moderate PID is defined as the absence of a tubo-ovarian abscess. Severe disease is defined as severe systemic symptoms or the presence of tubo-ovarian abscess. [1] 
INCIDENCE/ PREVALENCE
The exact incidence of PID is unknown because the disease cannot be diagnosed reliably from clinical symptoms and signs. [2] [3] [4] Direct visualisation of the fallopian tubes by laparoscopy is the best single diagnostic test, but it is invasive, lacks sensitivity, and is not used routinely in clinical practice. PID is the most common gynaecological reason for admission to hospital in the US, accounting for 18/10,000 recorded hospital discharges. [5] A diagnosis of PID is made in 1.1% of women aged 16 to 45 years attending their primary-care physician in England and Wales. [6] However, because most PID is asymptomatic, this figure under-estimates the true prevalence. [2] [7] A crude marker of PID in resource-poor countries can be obtained from reported hospital admission rates, where it accounts for 17% to 40% of gynaecological admissions in sub-Saharan Africa, 15% to 37% in Southeast Asia, and 3% to 10% in India. [8] 
AETIOLOGY/ RISK FACTORS
Factors associated with PID mirror those for STDs -young age, reduced socioeconomic circumstances, lower educational attainment, and recent new sexual partner. [3] [9] [10] Women considered at high risk for PID include those with prior infection with chlamydia or gonorrhoea, young age at onset of sexual activity, unprotected sexual intercourse with multiple partners, and prior history of PID. [1] Infection ascends from the cervix, and initial epithelial damage caused by bacteria (especially Chlamydia trachomatis and Neisseria gonorrhoeae) may allow the opportunistic entry of other organisms. Many different microbes, including Mycoplasma genitalium and anaerobes, may be isolated from the upper genital tract. [11] [12] The spread of infection to the upper genital tract can be increased by instrumentation of the cervix, but reduced by barrier methods of contraception, levonorgestrel implants, and by oral contraceptives compared with other forms of contraception. [13] [14] [15] [16] [17] PROGNOSIS PID has a high morbidity; about 20% of affected women become infertile, 40% develop chronic pelvic pain, and 1% of those who conceive have an ectopic pregnancy (see table 1, p 25 ) . [1] [18] Uncontrolled observations suggest that clinical symptoms and signs resolve in a significant proportion of untreated women. [1] 
AIMS OF INTERVENTION
To alleviate the pain and systemic malaise associated with infection; to achieve microbiological cure; to prevent development of permanent tubal damage with associated sequelae, such as chronic pelvic pain, ectopic pregnancy, and infertility; and to prevent the spread of infection to others, with minimal adverse effects.
OUTCOMES
Cure rate (includes clinical cure rate; microbiological cure of the upper genital tract; resolution of acute symptoms and signs); symptom severity (includes reduction of chronic pelvic pain); rate of ectopic pregnancy; fertility (includes pregnancy [other than ectopic]); rate of transmission to others; recurrence; quality of life; and adverse effects of treatment; in question on routine antibiotic prophylaxis: rate of PID.
METHODS
Clinical Evidence search September 2013. The following databases were used to identify studies for this systematic review: Medline 1966 to September 2013, Embase 1980 to September 2013, and The Cochrane Database of Systematic Reviews, issue 2, 2013 (1966 to date of issue). Additional searches were carried out in the Database of Abstracts of Reviews of Effects (DARE) and the Health Technology Assessment (HTA) database. We also searched for retractions of studies included in the review. Titles and abstracts identified by the initial search, run by an information specialist, were first assessed against predefined criteria by an evidence scanner. Full texts for potentially relevant studies were then assessed against predefined criteria by an evidence analyst. Studies selected for inclusion were discussed with an expert contributor. All data relevant to the review were then extracted by an evidence analyst. Study design criteria for inclusion in this review were: published systematic reviews and RCTs, at least single-blinded, and containing 20 or more individuals of whom more than 80% were followed up. There was no minimum length of follow-up. We excluded all studies described as 'open', 'open label', or not blinded unless blinding was impossible. We included RCTs and systematic reviews of RCTs, where harms of an included intervention were assessed, applying the same study design criteria for inclusion as we did for benefits. In addition, we use a regular surveillance protocol to capture harms alerts from organisations such as the FDA, the EMA, and the MHRA, which are added to the reviews as required. To aid readability of the numerical data in our reviews, we round many percentages to the nearest whole number. Readers should be aware of this when relating percentages to summary statistics such as relative risks (RRs) and odds ratios (ORs). We have performed a GRADE evaluation of the quality of evidence for interventions included in this review (see table, p 27 ). The categorisation of the quality of the evidence (high, moderate, low, or very low) reflects the quality of evidence available for our chosen outcomes in our defined populations of interest. These categorisations are not necessarily a reflection of the overall methodological quality of any individual study, because the Clinical Evidence population and outcome of choice may represent only a small subset of the total outcomes reported, and population included, in any individual trial. For further details of how we perform the GRADE evaluation and the scoring system we use, please see our website (www.clinicalevidence.com). • There is consensus that antibiotic treatment is more effective than no treatment for women with confirmed PID.
QUESTION

Benefits and harms
Different antibiotics versus each other:
We found one systematic review (search date 2004, 34 RCTs, 3548 women) [19] and four subsequent RCTs [20] [21]
[22] [23] assessing the effects of different antibiotic regimens in the treatment of pelvic inflammatory disease (PID). The review assessed standard antibiotic regimens and non-standard regimens; see table 2, p 25 for 'standard' and 'non-standard' regimens, as defined by the review. [19] The review identified no RCTs comparing standard or nonstandard regimens versus placebo (see Comment section).
-
Cure rate
Different antibiotics compared with each other We don't know how different antibiotic regimens compare with each other at improving cure rates in women with confirmed pelvic inflammatory disease (PID) (very low-quality evidence). In review [19] See Further information on studies [24] RCT The review reported that overall trial quality was poor 7/18 (39%) with clindamycin plus gentamicin for full details of population included in review Not significant RR 0.97 95% CI 0.83 to 1.12
Favours
Cure rate
46/55 (84%) with cefoxitin plus doxycycline 115 women
In review [19] See Further information on studies [25] RCT In review [19] See Further information on studies [26] RCT The review reported that overall trial quality was poor 87/104 (84%) with clindamycin plus gentamicin for full details of population included in review In review [19] See Further information on studies [27] RCT Overall effect size RR 1.01 57/63 (90%) with clindamycin plus gentamicin for full details of population included in review 95% CI 0.93 to 1.08
The review reported that overall trial quality was poor Not significant RR 0.90 95% CI 0.76 to 1.07
Cure rate
49/64 (77%) with ceftriaxone plus doxycycline 131 women
In review [19] See Further information on studies [28] RCT The review reported that overall trial quality was poor 57/67 (85%) with ciprofloxacin plus clindamycin for full details of population included in review In review [19] See Further information on studies [29] RCT The review reported that overall trial quality was poor 70/73 (96%) with clindamycin plus tobramycin for full details of population included in review Not significant RR 0.99 95% CI 0.82 to 1.20
Cure rate
75/121 (62%) with cefoxitin plus probenecid plus doxycycline 249 women
In review [19] See Further information on studies [30] RCT The review reported that overall trial quality was poor 80/128 (63%) with ofloxacin for full details of In review [19] See Further information on studies [31] RCT The review reported that overall trial quality was poor 28/31 (90%) with clindamycin plus amikacin for full details of population included in review In review [19] See Further information on studies [32] RCT The review reported that overall trial quality was poor 36 In review [19] See Further information on studies [33] RCT Overall In review [19] See Further information on studies [34] RCT The review reported that overall trial quality was poor 10/10 (100%) with ciprofloxacin for full details of population included in review In review [19] See Further information on studies [35] RCT The review reported that overall trial quality was poor 33 In review [19] See Further information on studies [36] RCT The review reported that overall trial quality was poor 33/33 (100%) with ciprofloxacin (plus clindamycin in one women) for full details of population included in review In review [19] See Further information on studies [37] RCT The review reported that overall trial quality was poor 41/44 (93%) with meropenem for full details of population included in review In review [19] See Further information on studies [38] RCT The review reported that overall trial quality was poor 37/37 (100%) with imipenem plus cilastin (plus doxycycline in some women) In review [19] See Further information on studies [39] RCT The review reported that overall trial quality was poor 23 In review [19] See Further information on studies [40] RCT Overall In review [19] See Further information on studies [41] RCT The review reported that overall trial quality was poor 9/39 (25%) with amoxicillin plus aminoglycoside plus metronidazole for full details of population included in review In review [19] See Further information on studies [42] RCT cline/tetracycline plus metronidazole
The review reported that overall trial quality was poor 10/10 (100%) with doxycycline plus oxytetracycline/tetracycline plus metronidazole for full details of population included in review In review [19] See Further information on studies [43] RCT The review reported that overall trial quality was poor 19 In review [19] See Further information on studies [45] RCT The review reported that overall trial quality was poor 15 In review [19] See Further information on studies [47] RCT The review reported that overall trial quality was poor 18/18 (100%) with meropenem for full details of population included in review In review [19] See Further information on studies [11] RCT The review reported that overall trial quality was poor 38 In review [19] See Further information on studies [49] RCT Overall effect size RR 0.80 15/16 (94%) with ciprofloxacin for full details of population included in review 95% CI 0.52 to 1.24
The review reported that overall trial quality was poor Not significant Difference +0.5% 95% CI -5.7% to +4.0%
Resolution of signs and symptoms , 5-24 days post-treatment
741 women with PID, without pelvic or tubo-ovarian abscess [20] RCT The review reported that overall trial quality was poor 262/289 (90.7%) with ofloxacin plus metronidazole 248/275 (90.2%) with moxifloxacin alone Not significant P >0.05 Clinical cure rate (defined as reduction of greater-than or equal to70% in severity score 669 women with uncomplicated acute PID [21] RCT and normal temperature and 669 women with uncomplicated acute PID [21] RCT plus normal temperature and leukocyte count) , 21-35 days post-treatment 206/343 (60%) with oral moxifloxacin for 14 days 191/326 (59%) with oral doxycycline plus oral metronidazole for 14 days plus one oral ciprofloxacin dose azithromycin P = 0.01 Cure rate (defined as absence or reduction of pelvic tender-120 women with mild PID treated in [23] RCT ness as compared to baseline pain levels) , day 14 -
Symptom severity
Different antibiotics compared with each other We don't know how different antibiotic regimens compare with each other at reducing symptoms in women with mild PID (low-quality evidence).
Favours
Effect size
Results and statistical analysis Outcome, Interventions Population
Ref (type)
Symptom severity
Not significant P = 0.23 Median VAS pain score (range 0-10) , day 14 120 women with mild PID treated in an outpatient setting [23] RCT 0.8 with doxycycline 0.4 with azithromycin plus placebo All women received a single intramuscular injection of ceftriaxone.
Not significant P = 0.59 Median McCormack pain score (range 0-3, total score defined as the sum of individual scores 120 women with mild PID treated in an outpatient setting [23] RCT for 12 abdominal and pelvic regions [maximum score = 36]) , day 14 4 with doxycycline 3 with azithromycin plus placebo All women received a single intramuscular injection of ceftriaxone.
-No data from the following reference on this outcome. [ -Recurrence Different antibiotics compared with each other We don't know how effective oral moxifloxacin and oral levofloxacin plus oral metronidazole are, compared with each other, at improving recurrence rates at 28-42 days post-treatment in women with confirmed PID (low-quality evidence).
Favours
Effect size
Results and statistical analysis Outcome, Interventions Population
Ref (type)
Recurrence
Significance not assessed Clinical recurrence/relapse (defined as reappearance of 460 women with PID with no pelvic [22] RCT signs and symptoms of PID) , 
Adverse effects (global)
Significance not assessed Adverse effect (any) 138 women [28] 52/69 (75%) with ceftriaxone plus doxycycline In review [19] RCT 57/69 (83%) with ciprofloxacin plus clindamycin Significance not assessed Adverse effects (any) 272 women [30] 20/134 (15%) with cefoxitin plus probenecid plus doxycycline In review [19] RCT [33] 9/35 (26%) with cefoxitin plus probenecid plus doxycycline In review [19] RCT 6/37 (26%) with ofloxacin Significance not assessed Adverse effect (any) 81 women [41] 5/42 (12%) with amoxicillin/clavulanate In review [19] RCT 2/39 (5%) with amoxicillin plus aminoglycoside plus metronidazole Significance not assessed Adverse effect (any) 36 women [49] 11/20 (55%) with doxycycline In review [19] RCT 3/16 (19%) with metronidazole Significance not assessed Adverse effect (any) 213 women [11] 32/107 (30%) with azithromycin plus metronidazole
In review [19] RCT 26/106 (25%) with azithromycin Significance not assessed Vestibular disturbance 170 women [25] 0/82 (0%) with cefoxitin plus doxycycline In review [19] RCT 3/88 (3%) with clindamycin plus gentamicin Significance not assessed Surgical intervention 120 women [25] 1/60 (2%) with cefoxitin plus doxycycline In review [19] RCT 1/60 (2%) with clindamycin plus gentamicin Not significant P = 0.14 Incidence of drug-related adverse event , 2-14 days posttreatment 669 women with uncomplicated acute PID [21] RCT 151/343 (44%) with oral moxifloxacin for 14 days 162/326 (50%) with oral doxycycline for 14 days plus one oral ciprofloxacin dose
Withdrawal from treatment owing to adverse effects
Significance not assessed Withdrawal from treatment 138 women [28] 1/69 (1%) with ceftriaxone plus doxycycline In review [19] RCT 1/69 (1%) with ciprofloxacin plus clindamycin Reason for withdrawal from ceftriaxone plus doxycycline arm given as GI disturbance
Significance not assessed Withdrew from study 80 women [35] 0/40 (0%) with clindamycin plus gentamicin In review [19] RCT 0/40 (0%) with ceftazidime plus doxycycline
Favours
Effect size
Results and statistical analysis Outcome, Interventions Population
Ref (type)
Significance not assessed Withdrew from study due to adverse effects 120 women
In review [19] [ 25] RCT 0/60 (0%) with cefoxitin plus doxycycline Significance not assessed Withdrawn from treatment due to at least 1 drug-related event 460 women with PID with no pelvic or tubo-ovarian ab- [22] RCT 4% with oral moxifloxacin for 14 days scess on pelvic ultrasonography and at laparoscopic ex-5% with oral levofloxacin plus oral metronidazole for 14 days amination, not requiring intravenous treatment
All women received a single intramuscular injection of ceftriaxone during days 4-7.
Angio-oedema
Significance not assessed Angio-oedema 81 women [41] 0/42 (0%) with amoxicillin/clavulanate In review [19] RCT 1/39 (3%) with amoxicillin plus aminoglycoside plus metronidazole
Favours
Effect size
Results and statistical analysis Outcome, Interventions Population
Ref (type) Allergy
Significance not assessed Rash 148 women [29] 2/75 (3%) with cefoxitin plus doxycycline In review [19] RCT 1/75 (1%) with clindamycin plus tobramycin Significance not assessed Rash 272 women [30] 1/134 (0.7%) with cefoxitin plus probenecid plus doxycycline In review [19] RCT 2/138 (1.4%) with ofloxacin Significance not assessed Incidence of drug-related rash , 2-14 days post-treatment 669 women with uncomplicated acute PID [21] RCT 8/343 (2%) with oral moxifloxacin for 14 days 10/326 (3%) with oral doxycyline plus oral metronidazole for 14 days plus one oral ciprofaloxacin dose
Significance not assessed Mild rash 130 women [27] 1/67(2%) with cefoxitin pus doxycycline In review [19] RCT 1/63 (2%) with clindamycin plus gentamicin Significance not assessed Allergy 72 women [33] 0/35 (0%) with cefoxitin plus probenecid plus doxycycline In review [19] RCT 1/37 (3%) with ofloxacin Significance not assessed Allergies 70 women [36] 0/35 (0%) with clindamycin plus gentamicin In review [19] RCT 2/35 (6%) with ciprofloxacin (plus clindamycin in 1 woman)
Significance not assessed Cutaneous allergy 44 women [43] 1/22 (5%) with amoxicillin/clavulanate In review [19] RCT 0/22 (0%) with ampicillin (or amoxicillin) plus gentamicin plus metronidazole Significance not assessed Pruritus 230 women [26] 2/114 (2%) with cefoxitin plus doxycycline In review [19] RCT 11/116 (9%) with clindamycin plus gentamicin
Gastrointestinal
Significance not assessed Gastrointestinal 170 women [25] 10/82 (12%) with cefoxitin plus doxycycline In review [19] RCT 15/88 (17%) with clindamycin plus gentamicin Not significant P = 0.057 Gastrointestinal 54/378 (14%) with moxifloxacin 741 women [20] RCT Favours Effect size
Results and statistical analysis Outcome, Interventions Population
Ref (type)
71/363 (20%) with ofloxacin plus metronidazole oral moxifloxacin P = 0.001 Incidence of any drug-related gastro-intestinal adverse 669 women with uncomplicated acute PID [21] RCT events , 2-14 days post-treatment 100/343 (29%) with oral moxifloxacin for 14 days 149/326 (46%) with oral doxycycline plus oral metronidazole for 14 days plus one oral ciprofloxacin dose
Significance not assessed Diarrhoea 130 women [27] 2/67 (3%) with cefoxitin plus doxycycline In review [19] RCT 2/63 (3%) with clindamycin plus gentamicin Significance not assessed Incidence of any drug-related diarrhoea , 2-14 days posttreatment 669 women with uncomplicated acute PID [21] RCT 26/343 (8%) with oral moxifloxacin for 14 days 24/326 (7%) with oral doxycycline plus oral metronidazole for 14 days plus one oral ciprofloxacin dose Significance not assessed Incidence of nausea , 28-42 days post-treatment 460 women with PID with no pelvic or tubo-ovarian ab- [22] RCT 42/228 (18.7%) with oral moxifloxacin for 14 days scess on pelvic ultrasonography and at laparoscopic ex-53/232 (23%) with oral levofloxacin plus oral metronidazole for 14 days amination, not requiring intravenous treatment All women received a single intramuscular injection of ceftriaxone during days 4-7.
Significance not assessed Nausea/vomiting 272 women [30] 19/134 (14%) with cefoxitin plus probenecid plus doxycycline In review [19] RCT 2/138 (1%) with ofloxacin Significance not assessed Nausea/vomiting 72 women [33] 
3/35 (9%) with cefoxitin plus probenecid plus doxycycline
In review [19] RCT 2/37 (5%) with ofloxacin Significance not assessed Incidence of drug-related nausea , 2-14 days post-treatment 669 women with uncomplicated acute PID [21] RCT 57/343 (17%) with oral moxifloxacin for 14 days 79/326 (24%) with oral doxycycline plus oral metronidazole for 14 days plus one oral ciprofloxacin dose
Significance not assessed Incidence of drug-related vomiting , 2-14 days post-treatment 669 women with uncomplicated acute PID [21] RCT 13/343 (4%) with oral moxifloxacin for 14 days
Favours
Effect size 36 /326 (11%) with oral doxycycline plus oral metronidazole for 14 days plus one oral ciprofloxacin dose
Results and statistical analysis Outcome, Interventions Population
Ref (type)
Significance not assessed Incidence of vomiting , 28-42 days post-treatment 460 women with PID with no pelvic or tubo-ovarian ab- [22] RCT 6/228 (2.7%) with oral moxifloxacin for 14 days scess on pelvic ultrasonography and at laparoscopic ex-15/232 (6.5%) with oral levofloxacin plus oral metronidazole for 14 days amination, not requiring intravenous treatment All women received a single intramuscular injection of ceftriaxone during days 4-7.
Significance not assessed Incidence of upper abdominal pain , 28-42 days post-treatment 460 women with PID with no pelvic or tubo-ovarian abscess on pelvic ul- [22] RCT 9/228 (4%) with oral moxifloxacin for 14 days trasonography and at laparoscopic examination, not re-13/232 (5.7%) with oral levofloxacin plus oral metronidazole for 14 days quiring intravenous treatment
Headaches/insomnia
Significance not assessed Insomnia 272 women [30] 0/134 (0%) with cefoxitin plus probenecid plus doxycycline In review [19] RCT 2/138 (1%) with ofloxacin Significance not assessed Headaches 72 women [33] 0/35 (0%) with cefoxitin plus probenecid plus doxycycline In review [19] RCT 1/37 (3%) with ofloxacin
Candidal vaginitis
Significance not assessed Candidal vaginitis 272 women [30] 6/134 (4%) with cefoxitin plus probenecid plus doxycycline In review [19] RCT 5/138 (4%) with ofloxacin Significance not assessed Candidal vaginitis 72 women [33] 2/35 (6%) with cefoxitin plus probenecid plus doxycycline In review [19] RCT 1/37 (3%) with ofloxacin
Severe adverse effects
Significance not assessed Severe adverse effects 213 women [11] 8/107 (7%) with azithromycin plus metronidazole In review [19] RCT 2/106 (2%) with azithromycin Significance not assessed Incidence of serious adverse events , 28-42 days post-treatment 460 women with PID with no pelvic or tubo-ovarian abscess on pelvic ul- [22] RCT Favours Effect size
Results and statistical analysis Outcome, Interventions Population
Ref (type)
3/228 (1.3%) with oral moxifloxacin for 14 days trasonography and at laparoscopic examination, not re-1/232 (0.4%) with oral levofloxacin plus oral metronidazole for 14 days quiring intravenous treatment All women received a single intramuscular injection of ceftriaxone during days 4-7.
Moxifloxacin group: colitis (n = 1), Stevens-Johnson syndrome (n = 1; identified as drug-related), miscarriage (n = 1). Levofloxacin/metronidazole group: acute pyelonephritis.
-No data from the following reference on this outcome. [23] ---Further information on studies [19] The review included women who had been either: diagnosed clinically or laparoscopically with PID; treated with any antibiotic combination; and with an outcome measure of clinical care, microbiological care, infertility, ectopic pregnancy, chronic pelvic pain, or any other relevant outcome. The review made no distinction for severity of disease or between intravenous and oral treatment.
--
Comment:
We found one systematic review (search date 1992, 21 studies), which reported on clinical and microbiological cure rates for various antibiotic regimens in the treatment of pelvic inflammatory disease (PID; see table 3, p 26 ). [50] The review provided aggregated data on indirect comparisons; aspects of the review were subsequently updated (search date 1997, 26 studies, 1925 women). [51] The earlier version of the review [50] examined all antimicrobial regimens, whereas the updated version [51] focused on anti-anaerobic treatment. The identified studies included case series, and it is not possible to ascertain from the aggregated data published how many studies were RCTs. Inclusion criteria were a diagnosis of PID (clinical, microbiological, laparoscopic, or by endometrial biopsy) and microbiological testing for Chlamydia trachomatis and Neisseria gonorrhoeae. The review found that antibiotics were effective in relieving the symptoms associated with PID, with clinical and microbiological cure rates of 88% to 100% (see table 2, p 26 ). The only regimen that seemed to perform less well was oral metronidazole plus doxycycline. However, the studies were of low power, and apparent differences in efficacy may have been confounded by differences in disease severity among studies.
Clinical guide:
We found no RCTs comparing antibiotics versus placebo or no treatment. However, such trials would be considered unethical because there is strong consensus that antibiotic treatments are more effective in women with pelvic inflammatory disease (PID) than no treatment. [52] We found little evidence about treatment of PID of differing severity, the effect of ethnicity, or the effects of tracing sexual contacts (see review on Partner notification). The risks of tubal occlusion and of subsequent infertility relate to the severity of PID before starting treatment. [53] Clinical improvement may not translate into preserved fertility.
[54] [55] The inclusion of observational studies in the older systematic review without a sensitivity analysis may compromise the validity of the conclusions. In the review, reliable comparison of different drugs may be confounded by possible differences in disease severity among the included studies. PARENTERAL ANTIBIOTICS. . . . . . . . . . . . . . . . . . . . . . . . . . . Pelvic inflammatory disease, see table, p 27 . • Oral antibiotics may be as effective as parenteral antibiotics in reducing symptoms and preserving fertility in women with mild to moderate PID, with fewer adverse effects. However, we don't know the optimal duration of treatment.
OPTION ORAL ANTIBIOTICS VERSUS
• For GRADE evaluation of interventions for
Benefits and harms
Oral antibiotics versus parenteral antibiotics:
We found one systematic review [19] containing three RCTs that compared oral versus parenteral antibiotic treatment. [1] [30] [33] -
Cure rate
Oral antibiotics compared with parenteral antibiotics Oral antibiotics and parenteral antibiotics may be equally effective at improving cure rate in women with uncomplicated PID (moderate-quality evidence).
Favours
Effect size
Results and statistical analysis Outcome, Interventions Population
Ref (type)
Cure rate
Not significant RR 1.03 95% CI 0.97 to 1.10
with oral ofloxacin 249 women with uncomplicated pelvic inflammatory disease (outpatient setting) [30] RCT with parenteral cefoxitin plus oral doxycycline In review [19] Absolute results not reported Not significant RR 0.97 95% CI 0.88 to 1.07
with oral ofloxacin 72 women with uncomplicated acute salpingitis (outpatient setting) [33] RCT with parenteral cefoxitin plus oral doxycycline In review [19] Absolute results not reported -No data from the following reference on this outcome. [1] -
Symptom severity
Oral antibiotics compared with parenteral antibiotics Oral antibiotics (given as an outpatient treatment) and parenteral antibiotics (given as an inpatient treatment) may be equally effective at improving tenderness, chronic pelvic pain, and endometriosis in women with mild to moderate PID (low-quality evidence).
Favours
Effect size
Results and statistical analysis Outcome, Interventions Population
Ref (type)
Symptom severity
Not significant P = 0.50 Tender on exam , 30 days 69/335 (21%) with single intramuscular dose of cefoxitin plus 831 women with mild to moderate PID [1] oral probenecid followed by oral doxycycline (outpatient)
In review [19] 63/324 (18%) with IV cefoxitin plus IV doxycycline followed by oral doxycycline (hospital admission for parenteral antibiotics; inpatient) Not significant P = 0.09 Endometritis (on biopsy) , 30 days 831 women with mild to moderate PID [1] RCT 102/222 (46%) with single intramuscular dose of cefoxitin plus In review [19] oral probenecid followed by oral doxycycline (outpatient) 85/226 (38%) with IV cefoxitin plus IV doxycycline followed by oral doxycycline (hospital admis-
Favours
Effect size
Results and statistical analysis Outcome, Interventions Population
Ref (type) sion for parenteral antibiotics; inpatient)
Significance not assessed Tubo-ovarian abscess , 30 days 831 women with mild to moderate PID [1] RCT 4/410 (0.9%) with single intramuscular dose of cefoxitin plus oral In review [19] probenecid followed by oral doxycycline (outpatient) 12/398 (0.7%) with IV cefoxitin plus IV doxycycline followed by oral doxycycline (hospital admission for parenteral antibiotics; inpatient) Not significant OR 1.24 95% CI 0.87 to 1.77
Chronic pelvic pain , 35 months
128/380 (34%) with single intramuscular dose of cefoxitin plus 831 women with mild to moderate PID In review [19] [1] RCT oral probenecid followed by oral doxycycline (outpatient) 110/369 (30%) with IV cefoxitin plus IV doxycycline followed by oral doxycycline (hospital admission for parenteral antibiotics; inpatient) -No data from the following reference on this outcome. [30] [33] -
Rate of ectopic pregnancy
Oral antibiotics compared with parenteral antibiotics Oral antibiotics (given as an outpatient treatment) and parenteral antibiotics (given as an inpatient treatment) are equally effective at reducing rate of ectopic pregnancy in women with mild to moderate PID (low-quality evidence). [1] RCT probenecid followed by oral doxycycline (outpatient)
Favours
Effect size
Results and statistical analysis Outcome, Interventions Population
Ref (type)
Rate of ectopic pregnancy
In review [19] 1/398 (0.3%) with IV cefoxitin plus IV doxycycline followed by oral doxycycline (hospital admission for parenteral antibiotics; inpatient) -No data from the following reference on this outcome. [30] [33] -
Fertility
Oral antibiotics compared with parenteral antibiotics Oral antibiotics (given as an outpatient treatment) and parenteral antibiotics (given as an inpatient treatment) may be equally effective at improving pregnancy or reducing infertility at 35 months in women with mild to moderate PID (low-quality evidence).
Favours
Effect size
Results and statistical analysis Outcome, Interventions Population
Ref (type) Pregnancy
Significance not assessed Pregnancy , 35 months 831 women with mild to moderate PID [1] RCT 174/410 (42%) with single intramuscular dose of cefoxitin plus In review [19] oral probenecid followed by oral doxycycline (outpatient) 166/398 (42%) with IV cefoxitin plus IV doxycycline followed by oral doxycycline (hospital admission for parenteral antibiotics; inpatient) [1] RCT oral probenecid followed by oral doxycycline (outpatient)
Infertility
In review [19] 67/347 (17.9%) with IV cefoxitin plus IV doxycycline followed by oral doxycycline (hospital admission for parenteral antibiotics; inpatient) -No data from the following reference on this outcome. [30] [33] -
Recurrence
Oral antibiotics compared with parenteral antibiotics Oral antibiotics (given as an outpatient treatment) and parenteral antibiotics (given as an inpatient treatment) may be equally effective at reducing recurrence of PID at 35 months (low-quality evidence). [1] RCT oral probenecid followed by oral doxycycline (outpatient)
Favours
In review [19] 66/398 (17%) with IV cefoxitin plus IV doxycycline followed by oral doxycycline (hospital admission for parenteral antibiotics; inpatient) -No data from the following reference on this outcome. [30] [33] -Rate of transmission to others --No data from the following reference on this outcome. [1] [30] [33] -Quality of life --No data from the following reference on this outcome. [ [30] RCT 15% with parenteral cefoxitin plus oral doxycycline In review [19] Absolute numbers not reported Adverse effects included nausea, thrombocytosis, candidal vaginitis, eosinophilia, monocytosis, headaches, and allergy Significance not assessed Adverse effects 72 women with uncomplicated acute salpingitis [33] RCT 16% with oral ofloxacin 26% with parenteral cefoxitin plus oral doxycycline In review [19] Absolute numbers not reported Adverse effects included nausea, thrombocytosis, candidal vaginitis, eosinophilia, monocytosis, headaches, and allergy Significance not assessed Adverse drug reaction 831 women with mild to moderate PID [1] RCT 7/410 (1.7%) with single intramuscular dose of cefoxitin plus oral In review [19] probenecid followed by oral doxycycline (outpatient) 6/398 (1.5%) with admission for parenteral antibiotics (inpatient)
Types of adverse event not reported
Significance not assessed Phlebitis , 30 days 831 women with mild to moderate PID [1] RCT 0/410 (0%) with single intramuscular dose of cefoxitin plus oral In review [19] probenecid followed by oral doxycycline (outpatient) 14/398 (3%) with IV cefoxitin plus IV doxycycline followed by oral doxycycline (hospital admission for parenteral antibiotics; inpatient) ----
Comment:
Clinical guide: Parenteral administration is indicated in people with severe PID (i.e., those with severe systemic symptoms or tubo-ovarian abscess), those who cannot tolerate fluids orally, and those with any other factor for hospitalisation (e.g., diagnostic uncertainty, pregnant or adolescent people, when severe disease precludes outpatient management, in people unable to follow or tolerate an outpatient regimen, in people who have not responded to outpatient therapy, when clinical follow-up cannot be arranged).
Parenteral treatment as an inpatient offers no advantage over outpatient treatment in women with mild-to-moderate pelvic inflammatory disease (defined as the absence of a tubo-ovarian abscess). Pelvic inflammatory disease, see table, p 27 . • We found no direct information about optimal durations of antibiotic treatment in women with PID. A 14-day treatment course is currently recommended.
OPTION
• For GRADE evaluation of interventions for
Benefits and harms
Different durations of antibiotics versus each other:
We identified two systematic reviews that assessed the effects of different antibiotic regimens in the treatment of PID. [19] [51] Neither review assessed the effect of duration of treatment on clinical outcomes, although the most common treatment period was 14 days.
-
Adverse effects
-
Favours
Effect size
Results and statistical analysis Outcome, Interventions Population
Ref (type)
Adverse effects
Adverse effects , 2 weeks
Number of people not reported [51] Systematic review with metronidazole plus doxycycline
The review reported that significant adverse effects such as pseudomembranous colitis, neuropathy, and drug reactions occur rarely (0.1%-0.5% of cases), and that minor adverse effects such as nausea, flushing, and metallic taste, occur in 30% to 50% of people after two weeks' treatment with metronidazole plus doxycycline -No data from the following reference on this outcome. [19] ----
Comment:
Clinical guide: A 14-day treatment course is recommended for pelvic inflammatory disease based on the current evidence.
QUESTION What are the effects of routine antibiotic prophylaxis to prevent pelvic inflammatory disease before IUD insertion?
OPTION ROUTINE ANTIBIOTIC PROPHYLAXIS BEFORE IUD INSERTION IN WOMEN AT HIGH RISK.
• For GRADE evaluation of interventions for Pelvic inflammatory disease, see table, p 27 .
• We found no direct information from RCTs about antibiotic prophylaxis before IUD insertion in women at high risk of pelvic inflammatory disease.
• Risks of PID may be increased after instrumentation of the cervix, and testing for infection before such procedures is advisable, but we don't know whether prophylactic antibiotics before IUD insertion reduce these risks.
Benefits and harms
Antibiotic prophylaxis before IUD insertion in women at high risk:
We found no RCTs on the effects of routine antibiotic prophylaxis in women at high risk of pelvic inflammatory disease.
----
Comment:
Nausea and vomiting has been reported with 17% to 28% of healthy volunteers on doxycycline, depending on the formulation given. [56] See the harms section of Antibiotics (for symptoms and microbiological clearance in women with confirmed pelvic inflammatory disease), p 3 .
OPTION ROUTINE ANTIBIOTIC PROPHYLAXIS BEFORE IUD INSERTION IN WOMEN AT LOW RISK. .
• Risks of PID may be increased after instrumentation of the cervix, and testing for infection before such procedures is advisable, but prophylactic antibiotics in women at low risk of PID seem no more effective than placebo at reducing rate of PID.
Benefits and harms
Antibiotic prophylaxis before IUD insertion versus no antibiotic prophylaxis (in women at low risk):
We found one systematic review (search date 2012, 6 RCTs, 5797 women requesting IUD insertion). [57] -
Rate of PID
Antibiotic prophylaxis before IUD insertion versus no antibiotic prophylaxis (in women at low risk) Antibiotic prophylaxis before IUD insertion seems no more effective than placebo or no treatment at reducing the incidence of pelvic inflammatory disease in women at low risk of PID (moderate-quality evidence). [57] Systematic review
Favours
Effect size
Results and statistical analysis Outcome, Interventions Population
Ref (type)
Rate of PID
The wide confidence interval suggests that the study may have lacked power to detect a clinically important difference 30/2891 (1.0%) with placebo (1 hour before IUD insertion) or no treatment
The rate of PID in all women was low (0.5%-1.6%), regardless of whether they received antibiotics, suggesting that this was a lowrisk group ---
Further information on studies
--
Comment:
Clinical guide:
In the populations included in the systematic review, the risk of PID after IUD insertion was low. [57] The occurrence of PID in this group usually reflects the introduction of infection into the uterus during IUD insertion, and will therefore vary with the prevalence of STDs in the population. A further systematic review also found that the absolute risk of PID was low even when gonorrhoea or chlamydia was present at the time of IUD insertion (0%-5% for those with an STD compared with 0%-2% in those without an STD). [58] GLOSSARY Low-quality evidence Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Moderate-quality evidence Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Very low-quality evidence Any estimate of effect is very uncertain.
SUBSTANTIVE CHANGES
Antibiotics (for symptoms and microbiological clearance in women with confirmed pelvic inflammatory disease) Three RCTs added; [21] [23] [22] categorisation unchanged (likely to be beneficial).
Routine antibiotic prophylaxis before IUD insertion in women at low risk One previously included systematic review updated and new data added. [57] Categorisation unchanged (unlikely to be beneficial). 12% v 17%; OR 0.69, 95% CI 0.43 to 1.09 831 women with mild to moderate PID; 808 followed up to 35 months; inpatients v outpatients [1] 1.2% v 0.2%; OR 4.91, 95% CI 0.57 to 42.25
17% v 21%; OR 0.88, 95% CI 0.59 to 1.32
41% v 45%; OR 1.21, 95% CI 0.87 to 1.67 18% v 24%; OR 0.71, 95% CI 0.48 to 1.05 As above; 541 followed up to 84 months; inpatients v outpatients [18] PID, pelvic inflammatory disease [19] [20] [21] [22] [23] Quality point deducted for sparse data; directness point deducted for short follow-up Low 0 -1 0 -1 4 Different antibiotics versus each other Symptom severity 1 (120) [23] Quality points deducted for incomplete reporting of results; directness point deducted due to short-term follow-up (unclear whether recurrence or relapse) Low 0 -1 0 -1 4 Different antibiotics versus each other Recurrence 1 (460) [22] Quality point deducted for incomplete reporting of results. Directness point deducted for inclusion of oral antibiotics in parenteral arm Low 0 -1 0 -1 4 Oral antibiotics versus parenteral antibiotics Cure rate 2 (321) [30] [33] Quality point deducted for no statistical assessment. Directness point deducted for inclusion of intramuscular injection in outpatient arm and oral antibiotics in parenteral arm Low 0 -1 0 -1 4 Oral antibiotics versus parenteral antibiotics Symptom severity 1 (831) [1] Quality point deducted for no statistical assessment. Directness point deducted for inclusion of intramuscular injection in outpatient arm Low 0 -1 0 -1 4 Oral antibiotics versus parenteral antibiotics Rate of ectopic pregnancy 1 (831) [1] Quality point deducted for no statistical assessment for some outcomes. Directness point deducted for inclusion of intramuscular injection in outpatient arm Low 0 -1 0 -1 4 Oral antibiotics versus parenteral antibiotics Fertility 1 (831) [1] Quality point deducted for no statistical assessment. Directness point deducted for inclusion of intramuscular injection in outpatient arm Low 0 -1 0 -1 4 Oral antibiotics versus parenteral antibiotics Recurrence 1 (831) [1] What are the effects of routine antibiotic prophylaxis to prevent pelvic inflammatory disease before IUD insertion?
Directness point deducted for small number of events Moderate 0 -1 0 0 4 Antibiotic prophylaxis before IUD insertion versus no antibiotic prophylaxis (in women at low risk) Rate of PID 6 (5797) [57] We initially allocate 4 points to evidence from RCTs, and 2 points to evidence from observational studies. To attain the final GRADE score for a given comparison, points are deducted or added from this initial score based on preset criteria relating to the categories of quality, directness, consistency, and effect size. Quality: based on issues affecting methodological rigour (e.g., incomplete reporting of results, quasirandomisation, sparse data [<200 people in the analysis]). Consistency: based on similarity of results across studies. Directness: based on generalisability of population or outcomes. Effect size: based on magnitude of effect as measured by statistics such as relative risk, odds ratio, or hazard ratio.
